RÉSUMÉ
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.
Sujet(s)
Tumeurs du côlon , Humains , Tumeurs du côlon/diagnostic , Tumeurs du côlon/thérapie , Tumeurs du côlon/anatomopathologie , Tumeurs du côlon/traitement médicamenteux , Oncologie médicale/normes , Oncologie médicale/méthodes , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , États-UnisRÉSUMÉ
Engrailed-1 (EN1) is a critical homeodomain transcription factor (TF) required for neuronal survival, and EN1 expression has been shown to promote aggressive forms of triple negative breast cancer. Here, it is reported that EN1 is aberrantly expressed in a subset of pancreatic ductal adenocarcinoma (PDA) patients with poor outcomes. EN1 predominantly repressed its target genes through direct binding to gene enhancers and promoters, implicating roles in the activation of MAPK pathways and the acquisition of mesenchymal cell properties. Gain- and loss-of-function experiments demonstrated that EN1 promoted PDA transformation and metastasis in vitro and in vivo. The findings nominate the targeting of EN1 and downstream pathways in aggressive PDA.
Sujet(s)
Carcinome du canal pancréatique , Tumeurs du pancréas , Humains , Facteurs de transcription/génétique , Facteurs de transcription/métabolisme , Tumeurs du pancréas/génétique , Régulation de l'expression des gènes , Carcinome du canal pancréatique/génétiqueRÉSUMÉ
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
Sujet(s)
Tumeurs de l'anus , Carcinome épidermoïde , Humains , Biopsie , Oncologie médicaleRÉSUMÉ
Cancer alters the function of multiple organs beyond those targeted by metastasis1,2. Here we show that inflammation, fatty liver and dysregulated metabolism are hallmarks of systemically affected livers in mouse models and in patients with extrahepatic metastasis. We identified tumour-derived extracellular vesicles and particles (EVPs) as crucial mediators of cancer-induced hepatic reprogramming, which could be reversed by reducing tumour EVP secretion via depletion of Rab27a. All EVP subpopulations, exosomes and principally exomeres, could dysregulate hepatic function. The fatty acid cargo of tumour EVPs-particularly palmitic acid-induced secretion of tumour necrosis factor (TNF) by Kupffer cells, generating a pro-inflammatory microenvironment, suppressing fatty acid metabolism and oxidative phosphorylation, and promoting fatty liver formation. Notably, Kupffer cell ablation or TNF blockade markedly decreased tumour-induced fatty liver generation. Tumour implantation or pre-treatment with tumour EVPs diminished cytochrome P450 gene expression and attenuated drug metabolism in a TNF-dependent manner. We also observed fatty liver and decreased cytochrome P450 expression at diagnosis in tumour-free livers of patients with pancreatic cancer who later developed extrahepatic metastasis, highlighting the clinical relevance of our findings. Notably, tumour EVP education enhanced side effects of chemotherapy, including bone marrow suppression and cardiotoxicity, suggesting that metabolic reprogramming of the liver by tumour-derived EVPs may limit chemotherapy tolerance in patients with cancer. Our results reveal how tumour-derived EVPs dysregulate hepatic function and their targetable potential, alongside TNF inhibition, for preventing fatty liver formation and enhancing the efficacy of chemotherapy.
Sujet(s)
Vésicules extracellulaires , Acides gras , Stéatose hépatique , Foie , Tumeurs du pancréas , Animaux , Souris , Cytochrome P-450 enzyme system/génétique , Vésicules extracellulaires/métabolisme , Acides gras/métabolisme , Stéatose hépatique/traitement médicamenteux , Stéatose hépatique/étiologie , Stéatose hépatique/métabolisme , Stéatose hépatique/prévention et contrôle , Foie/métabolisme , Foie/anatomopathologie , Foie/physiopathologie , Tumeurs du pancréas/métabolisme , Tumeurs du pancréas/anatomopathologie , Microenvironnement tumoral , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Facteur de nécrose tumorale alpha/métabolisme , Tumeurs du foie/secondaire , Humains , Inflammation/métabolisme , Acide palmitique/métabolisme , Cellules de Küpffer , Phosphorylation oxydative , Protéines rab27 liant le GTP/déficitRÉSUMÉ
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a "watch-and-wait" nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
Sujet(s)
Tumeurs du rectum , Humains , Oncologie médicale , Traitement néoadjuvant , Tumeurs du rectum/diagnostic , Tumeurs du rectum/anatomopathologie , Tumeurs du rectum/thérapieRÉSUMÉ
BACKGROUND: Radiation therapy (RT) has a suboptimal effect in patients with pancreatic ductal adenocarcinoma (PDAC) due to intrinsic and acquired radioresistance (RR). Comprehensive bioinformatics and microarray analysis revealed that cholesterol biosynthesis (CBS) is involved in the RR of PDAC. We now tested the inhibition of the CBS pathway enzyme, farnesyl diphosphate synthase (FDPS), by zoledronic acid (Zol) to enhance radiation and activate immune cells. METHODS: We investigated the role of FDPS in PDAC RR using the following methods: in vitro cell-based assay, immunohistochemistry, immunofluorescence, immunoblot, cell-based cholesterol assay, RNA sequencing, tumouroids (KPC-murine and PDAC patient-derived), orthotopic models, and PDAC patient's clinical study. FINDINGS: FDPS overexpression in PDAC tissues and cells (P < 0.01 and P < 0.05) is associated with poor RT response and survival (P = 0.024). CRISPR/Cas9 and pharmacological inhibition (Zol) of FDPS in human and mouse syngeneic PDAC cells in conjunction with RT conferred higher PDAC radiosensitivity in vitro (P < 0.05, P < 0.01, and P < 0.001) and in vivo (P < 0.05). Interestingly, murine (P = 0.01) and human (P = 0.0159) tumouroids treated with Zol+RT showed a significant growth reduction. Mechanistically, RNA-Seq analysis of the PDAC xenografts and patients-PBMCs revealed that Zol exerts radiosensitization by affecting Rac1 and Rho prenylation, thereby modulating DNA damage and radiation response signalling along with improved systemic immune cells activation. An ongoing phase I/II trial (NCT03073785) showed improved failure-free survival (FFS), enhanced immune cell activation, and decreased microenvironment-related genes upon Zol+RT treatment. INTERPRETATION: Our findings suggest that FDPS is a novel radiosensitization target for PDAC therapy. This study also provides a rationale to utilize Zol as a potential radiosensitizer and as an immunomodulator in PDAC and other cancers. FUNDING: National Institutes of Health (P50, P01, and R01).
Sujet(s)
Carcinome du canal pancréatique , Tumeurs du pancréas , Animaux , Carcinome du canal pancréatique/traitement médicamenteux , Carcinome du canal pancréatique/génétique , Carcinome du canal pancréatique/radiothérapie , Lignée cellulaire tumorale , Prolifération cellulaire , Altération de l'ADN , Régulation de l'expression des gènes tumoraux , Geranyltranstransferase/génétique , Geranyltranstransferase/métabolisme , Humains , Souris , Tumeurs du pancréas/génétique , Tumeurs du pancréas/métabolisme , Tumeurs du pancréas/radiothérapie , Transduction du signal , Microenvironnement tumoral/génétique , Protéine G rac1/génétique , Protéine G rac1/métabolismeRÉSUMÉ
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation-positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Sujet(s)
Tumeurs du côlon , Produits pharmaceutiques biosimilaires , Tumeurs du côlon/diagnostic , Tumeurs du côlon/génétique , Tumeurs du côlon/thérapie , Réparation de mésappariement de l'ADN , Humains , Instabilité des microsatellites , MutationRÉSUMÉ
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E- or HER2 amplification-positive disease.
Sujet(s)
Tumeurs du côlon , Tumeurs du rectum , Tumeurs du côlon/diagnostic , Tumeurs du côlon/thérapie , Humains , Traitement néoadjuvant , Guides de bonnes pratiques cliniques comme sujet , Tumeurs du rectum/diagnostic , Tumeurs du rectum/thérapieRÉSUMÉ
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease that can be separated into distinct subtypes based on molecular signatures. Identifying PDAC subtype-specific therapeutic vulnerabilities is necessary to develop precision medicine approaches to treat PDAC. EXPERIMENTAL DESIGN: A total of 56 PDAC liver metastases were obtained from the UNMC Rapid Autopsy Program and analyzed with quantitative proteomics. PDAC subtypes were identified by principal component analysis based on protein expression profiling. Proteomic subtypes were further characterized by the associated clinical information, including but not limited to survival analysis, drug treatment response, and smoking and drinking status. RESULTS: Over 3,960 proteins were identified and used to delineate four distinct PDAC microenvironment subtypes: (i) metabolic; (ii) progenitor-like; (iii) proliferative; and (iv) inflammatory. PDAC risk factors of alcohol and tobacco consumption correlate with subtype classifications. Enhanced survival is observed in FOLFIRINOX treated metabolic and progenitor-like subtypes compared with the proliferative and inflammatory subtypes. In addition, TYMP, PDCD6IP, ERAP1, and STMN showed significant association with patient survival in a subtype-specific manner. Gemcitabine-induced alterations in the proteome identify proteins, such as serine hydroxymethyltransferase 1, associated with drug resistance. CONCLUSIONS: These data demonstrate that proteomic analysis of clinical PDAC liver metastases can identify molecular signatures unique to disease subtypes and point to opportunities for therapeutic development to improve the treatment of PDAC.
Sujet(s)
Adénocarcinome/anatomopathologie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Marqueurs biologiques tumoraux/métabolisme , Carcinome du canal pancréatique/anatomopathologie , Tumeurs du foie/secondaire , Tumeurs du pancréas/anatomopathologie , Protéome/métabolisme , Adénocarcinome/traitement médicamenteux , Adénocarcinome/métabolisme , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Carcinome du canal pancréatique/traitement médicamenteux , Carcinome du canal pancréatique/métabolisme , Lignée cellulaire tumorale , Désoxycytidine/administration et posologie , Désoxycytidine/analogues et dérivés , Femelle , Fluorouracil/administration et posologie , Régulation de l'expression des gènes tumoraux , Humains , Irinotécan/administration et posologie , Leucovorine/administration et posologie , Tumeurs du foie/traitement médicamenteux , Tumeurs du foie/métabolisme , Mâle , Typage moléculaire/méthodes , Oxaliplatine/administration et posologie , Tumeurs du pancréas/classification , Tumeurs du pancréas/traitement médicamenteux , Tumeurs du pancréas/métabolisme , Protéome/analyse , Protéomique/méthodes , Taux de survie , Résultat thérapeutique ,RÉSUMÉ
OBJECTIVE: Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), followed by stereotactic body radiotherapy (SBRT) with the radiosensitizer nelfinavir. MATERIALS AND METHODS: Following imaging, pathologic confirmation, and staging laparoscopy, subjects received three 3-week cycles of CIT (gemcitabine/leucovorin/fluorouracil/oregovomab). Thereafter, nelfinavir was delivered (1250 mg bid) for 5 weeks, with SBRT (40 Gy/5 fractions) occurring during the third week of nelfinavir. Following another cycle of CIT, pancreaticoduodenectomy was performed if resectable. Three more cycles of CIT were then delivered (total 7 cycles). In subjects with high (≥10 U/mL) CA-125, oregovomab (2 mg) was administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively). The enzyme-linked immunospot assay evaluated the development of CA-125-specific CD8 T-lymphocytes. RESULTS: The trial was prematurely closed because gemcitabine/leucovorin/fluorouracil was replaced by FOLFIRINOX and gemcitabine/nab-paclitaxel as the standard of care. Median follow-up was 13 months. Of 11 enrolled patients, 10 had high CA-125; 1 patient suffered an unexpected cardiac-related death, so 9 subjects received oregovomab. Ten received SBRT and 4 underwent resection. Overall, 6/11 patients experienced any grade ≥3 event. The median survival and time to progression were 13 and 8.6 months, respectively. Five patients had samples available for immunospot testing, of whom 2 (40%) developed CA-125-specific CD8 T-lymphocytes. CONCLUSION: A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity. Re-evaluation with modern systemic paradigms is recommended.
Sujet(s)
Adénocarcinome/thérapie , Anticorps monoclonaux d'origine murine/usage thérapeutique , Nelfinavir/usage thérapeutique , Traitement néoadjuvant/méthodes , Tumeurs du pancréas/thérapie , Radiochirurgie/méthodes , Adénocarcinome/imagerie diagnostique , Adénocarcinome/mortalité , Adénocarcinome/anatomopathologie , Adulte , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Antigènes CA-125/sang , Camptothécine/effets indésirables , Camptothécine/analogues et dérivés , Camptothécine/usage thérapeutique , Association thérapeutique , Survie sans rechute , Femelle , Fluorouracil/effets indésirables , Fluorouracil/usage thérapeutique , Études de suivi , Humains , Estimation de Kaplan-Meier , Leucovorine/effets indésirables , Leucovorine/usage thérapeutique , Imagerie par résonance magnétique/méthodes , Mâle , Protéines membranaires/sang , Adulte d'âge moyen , Nelfinavir/effets indésirables , Invasion tumorale/anatomopathologie , Composés organiques du platine/effets indésirables , Composés organiques du platine/usage thérapeutique , Tumeurs du pancréas/imagerie diagnostique , Tumeurs du pancréas/mortalité , Tumeurs du pancréas/anatomopathologie , Duodénopancréatectomie/méthodes , Modèles des risques proportionnels , Appréciation des risques , Analyse de survie , Facteurs temps , Tomodensitométrie/méthodes , Résultat thérapeutiqueRÉSUMÉ
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.
Sujet(s)
Adénocarcinome/diagnostic , Adénocarcinome/thérapie , Tumeurs de l'intestin/diagnostic , Tumeurs de l'intestin/thérapie , Intestin grêle/anatomopathologie , Guides de bonnes pratiques cliniques comme sujet , Adénocarcinome/étiologie , Adénocarcinome/mortalité , Association thérapeutique , Diagnostic différentiel , Humains , Tumeurs de l'intestin/étiologie , Tumeurs de l'intestin/mortalité , Stadification tumorale , Facteurs de risque , Survie (démographie) , Résultat thérapeutique , Observation (surveillance clinique)RÉSUMÉ
INTRODUCTION: The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects. There have been no studies evaluating combined stereotactic body radiotherapy (SBRT) and NFV for borderline/unresectable pancreatic cancer. The primary objective of this phase I trial (NCT01068327) was to determine the maximum tolerated SBRT/NFV dose, and secondarily evaluate outcomes. METHODS: Following initial imaging, pathologic confirmation, and staging laparoscopy, subjects initially received three 3-week cycles of gemcitabine/leucovorin/fluorouracil; patients without radiologic progression received 5-fraction SBRT/NFV. Dose escalation was as follows: (1) 25â¯Gy/625â¯mg BID ×3wks; (2) 25â¯Gy/1250â¯mg BID ×3wks; (3) 30â¯Gy/1250â¯mg BID ×3wks; (4) 35â¯Gy/1250â¯mg BID ×3wks; (5) 35â¯Gy/1250â¯mg BID ×5wks; and (6) 40â¯Gy/1250â¯mg BID ×5wks. Pancreaticoduodenectomy was performed thereafter if resectable; if not, gemcitabine/leucovorin/fluorouracil was administered. RESULTS: Forty-six patients enrolled (10/2008-5/2013); 39 received protocol-directed therapy. Sixteen (41%) experienced any grade ≥2 event during and 1â¯month after SBRT. Four grade 3 and both grade 4 events occurred in a single patient at the initial dose level. 40â¯Gy/1250â¯mg BID ×5wks was the maximum tolerated dose. Five patients had late gastrointestinal bleeding (nâ¯=â¯2 superior mesenteric artery pseudo-aneurysm, nâ¯=â¯1 disease progression, nâ¯=â¯1 lower GI tract, nâ¯=â¯1 unknown location). The median overall survival was 14.4â¯months. Six (15%) patients recurred locally; median local failure-free survival was not reached. The median distant failure-free survival was 11â¯months, and median all failure-free survival was 10â¯months. CONCLUSIONS: Concurrent SBRT (40â¯Gy)/NFV (1250â¯mg BID) for locally advanced pancreatic cancer is feasible and safe, although careful attention to treatment planning parameters is recommended to reduce the incidence of late gastrointestinal bleeding.
Sujet(s)
Adénocarcinome/radiothérapie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Nelfinavir/administration et posologie , Tumeurs du pancréas/radiothérapie , Radiosensibilisants/administration et posologie , Radiochirurgie/méthodes , Adénocarcinome/traitement médicamenteux , Adénocarcinome/anatomopathologie , Adénocarcinome/chirurgie , Adulte , Sujet âgé , Chimioradiothérapie adjuvante , Désoxycytidine/administration et posologie , Désoxycytidine/analogues et dérivés , Évolution de la maladie , Femelle , Fluorouracil/administration et posologie , Humains , Leucovorine/administration et posologie , Mâle , Adulte d'âge moyen , Traitement néoadjuvant , Récidive tumorale locale/anatomopathologie , Tumeurs du pancréas/traitement médicamenteux , Tumeurs du pancréas/anatomopathologie , Tumeurs du pancréas/chirurgie , Duodénopancréatectomie , Radiochirurgie/effets indésirables ,RÉSUMÉ
The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain lesions can be treated with margin-negative local excision alone. Disease surveillance is recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is essential for optimal patient care.
Sujet(s)
Tumeurs de l'anus/thérapie , Carcinome épidermoïde/thérapie , Oncologie médicale/normes , Récidive tumorale locale/thérapie , Sociétés médicales/normes , Canal anal/anatomopathologie , Canal anal/chirurgie , Protocoles de polychimiothérapie antinéoplasique/normes , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs de l'anus/diagnostic , Tumeurs de l'anus/épidémiologie , Tumeurs de l'anus/anatomopathologie , Biopsie , Carcinome épidermoïde/diagnostic , Carcinome épidermoïde/épidémiologie , Carcinome épidermoïde/anatomopathologie , Chimioradiothérapie/méthodes , Chimioradiothérapie/normes , Colostomie/normes , Survie sans rechute , Humains , Récidive tumorale locale/diagnostic , Récidive tumorale locale/épidémiologie , Récidive tumorale locale/anatomopathologie , Équipe soignante/normes , Essais contrôlés randomisés comme sujet , États-Unis/épidémiologieRÉSUMÉ
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, and survivorship in patients with rectal cancer. This portion of the guidelines focuses on the management of localized disease, which involves careful patient selection for curative-intent treatment options that sequence multimodality therapy usually comprised of chemotherapy, radiation, and surgical resection.
Sujet(s)
Oncologie médicale/normes , Récidive tumorale locale/thérapie , Tumeurs du rectum/thérapie , Sociétés médicales/normes , Protocoles de polychimiothérapie antinéoplasique/normes , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Biopsie , Chimioradiothérapie/méthodes , Chimioradiothérapie/normes , Survie sans rechute , Humains , Incidence , Chimiothérapie d'induction/méthodes , Traitement néoadjuvant/méthodes , Traitement néoadjuvant/normes , Récidive tumorale locale/diagnostic , Récidive tumorale locale/épidémiologie , Récidive tumorale locale/anatomopathologie , Stadification tumorale , Sélection de patients , Proctectomie/méthodes , Proctectomie/normes , Essais contrôlés randomisés comme sujet , Tumeurs du rectum/diagnostic , Tumeurs du rectum/épidémiologie , Tumeurs du rectum/anatomopathologie , Rectum/anatomopathologie , Rectum/chirurgie , États-Unis/épidémiologie , Observation (surveillance clinique)/méthodes , Observation (surveillance clinique)/normesRÉSUMÉ
Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.Significance: New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. Cancer Discov; 8(9); 1112-29. ©2018 AACR.See related commentary by Collisson, p. 1062This article is highlighted in the In This Issue feature, p. 1047.
Sujet(s)
Antinéoplasiques/pharmacologie , Analyse de profil d'expression de gènes/méthodes , Réseaux de régulation génique/effets des médicaments et des substances chimiques , Organoïdes/effets des médicaments et des substances chimiques , Tumeurs du pancréas/anatomopathologie , Antinéoplasiques/usage thérapeutique , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Tests de criblage d'agents antitumoraux , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Humains , Thérapie moléculaire ciblée , Organoïdes/composition chimique , Organoïdes/cytologie , Tumeurs du pancréas/traitement médicamenteux , Tumeurs du pancréas/génétique , Médecine de précision , Études prospectives , Analyse de séquence d'ARN , Norme de soins , Cellules cancéreuses en cultureRÉSUMÉ
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
Sujet(s)
Tumeurs du côlon/diagnostic , Tumeurs du côlon/thérapie , Tumeurs du côlon/étiologie , HumainsRÉSUMÉ
BACKGROUND: The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors. METHODS: TS protein expression was determined in mCRC tissue. Patients who had TS-L tumors received FOLFOX/Bev, and those who had TS-H tumors were randomly assigned to receive either FOLFOX/Bev or IROX/Bev. The primary endpoint was the response rate (complete plus partial responses). RESULTS: In total, 211 of 247 patients (70% TS-H) were registered to the treatment phase. Efficacy analyses included eligible patients who had started treatment (N = 186). The response rates for patients who received IROX/Bev (TS-H), FOLFOX/Bev (TS-H), and FOLFOX/Bev (TS-L) were 33%, 38%, and 49%, respectively (P = nonsignificant). The median progression-free survival (PFS) was 10 months (95% confidence interval [CI], 9-12 months; 10 months in the IROX/Bev TS-H group, 9 months in the FOLFOX/Bev TS-H group, and 13 months in the FOLFOX/Bev TS-L group). The TS-L group had improved PFS compared with the TS-H group that received FOLFOX/Bev (hazard ratio, 1.6; 95% CI, 1.0%-2.4%; P = .04; Cox regression). The median overall survival (OS) was 22 months (95% CI, 20 29 months; 18 months in the IROX/Bev TS-H group, 21 months in the FOLFOX/Bev TS-H group, and 32 months in the TS-L group). OS comparisons for the 2 TS-H arms and for the FOLFOX/Bev TS-H versus TS-L arms were not significantly different. CONCLUSIONS: TS expression was prognostic: Patients with TS-L tumors who received FOLFOX/Bev had a longer PFS than those with TS-H tumors, along with a trend toward longer OS. Patients with TS-H tumors did not benefit more from IROX/Bev than from FOLFOX/Bev. Cancer 2018;124:688-97. © 2017 American Cancer Society.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs colorectales/traitement médicamenteux , Thymidylate synthase/biosynthèse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Bévacizumab/administration et posologie , Tumeurs colorectales/enzymologie , Tumeurs colorectales/anatomopathologie , Femelle , Fluorouracil/administration et posologie , Humains , Immunohistochimie , Estimation de Kaplan-Meier , Leucovorine/administration et posologie , Mâle , Adulte d'âge moyen , Métastase tumorale , Oxaliplatine/administration et posologie , Pronostic , Modèles des risques proportionnels , Résultat thérapeutiqueRÉSUMÉ
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metastasis. Here, we used an organoid culture system to investigate how transcription and the enhancer landscape become altered during discrete stages of disease progression in a PDA mouse model. This approach revealed that the metastatic transition is accompanied by massive and recurrent alterations in enhancer activity. We implicate the pioneer factor FOXA1 as a driver of enhancer activation in this system, a mechanism that renders PDA cells more invasive and less anchorage-dependent for growth in vitro, as well as more metastatic in vivo. In this context, FOXA1-dependent enhancer reprogramming activates a transcriptional program of embryonic foregut endoderm. Collectively, our study implicates enhancer reprogramming, FOXA1 upregulation, and a retrograde developmental transition in PDA metastasis.
Sujet(s)
Adénocarcinome/génétique , Carcinome du canal pancréatique/génétique , Éléments activateurs (génétique) , Régulation de l'expression des gènes tumoraux , Facteur nucléaire hépatocytaire HNF-3 alpha/génétique , Tumeurs du pancréas/génétique , Adénocarcinome/métabolisme , Adénocarcinome/anatomopathologie , Animaux , Carcinome du canal pancréatique/métabolisme , Carcinome du canal pancréatique/anatomopathologie , Lignée cellulaire tumorale , Modèles animaux de maladie humaine , Épigénomique , Femelle , Analyse de profil d'expression de gènes , Humains , Mâle , Souris , Souris de lignée C57BL , Métastase tumorale , Organoïdes/métabolisme , Pancréas/métabolisme , Tumeurs du pancréas/métabolisme , Tumeurs du pancréas/anatomopathologieRÉSUMÉ
Poor response to cancer therapy due to resistance remains a clinical challenge. The present study establishes a widely prevalent mechanism of resistance to gemcitabine in pancreatic cancer, whereby increased glycolytic flux leads to glucose addiction in cancer cells and a corresponding increase in pyrimidine biosynthesis to enhance the intrinsic levels of deoxycytidine triphosphate (dCTP). Increased levels of dCTP diminish the effective levels of gemcitabine through molecular competition. We also demonstrate that MUC1-regulated stabilization of hypoxia inducible factor-1α (HIF-1α) mediates such metabolic reprogramming. Targeting HIF-1α or de novo pyrimidine biosynthesis, in combination with gemcitabine, strongly diminishes tumor burden. Finally, reduced expression of TKT and CTPS, which regulate flux into pyrimidine biosynthesis, correlates with better prognosis in pancreatic cancer patients on fluoropyrimidine analogs.